SAGES Magazine

THE SOUTH AFRICAN GASTROENTEROLOGY REVIEW 2022 | VOLUME 20 | ISSUE 3 | 12 References: 1. Blignaut C. Amgen launches AMGEVITA™ a biosimilar to adalimumab, in South Africa. Medpharm Publications. May 14, 2020. Available from https://medpharm.co.za/ home-featured/amgen-launches-amgevitatm-a-biosimilar-to-adalimumab-in-south-africa/ 2. Lapadula G, Marchesoni A, Armuzzi A, et al. Adalimumab in the treatment of immune- mediated diseases. Int J Immunopathology & Pharmacology 2014;27(S1):L33-48. 3. AMGEVITA ® professional information. 26 Aug 2021. 4. Laursen T, Hansen B, Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic & Clinical Pharmacology & Toxicology 2006;98:218-221. 5. AMGEN Fact Sheet. 2021. Accessed January 27, 2022. Available from https://wwwext.amgen.com/pdfs/misc/Fact_Sheet_Amgen.pdf *AMGEVITA ® is indicated for inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, moderate-to-severe chronic plaque psoriasis, severe axial spondyloarthritis, severe active ankylosing spondylitis, moderate-to-severe Crohn’s disease, moderate-to severe ulcerative colitis, hipradenitis suppurativa and uveitis. 2,3 AMGEVITA ® is also indicated for the treatment of paediatric inflammatory diseases, including polyarticular juvenile idiopathic arthritis, paediatric Crohn’s disease, paediatric plaque psoriasis and paediatric uveitis. 3 THE ADALIMUMAB FROM AMGEN 1 A BIOTECHNOLOGY INNOVATOR SINCE 1980 5 For the treatment of a wide range of immune-mediated inflammatory diseases (IMIDs) in adults and children* 2,3 S4 AMGEVITA ® 20 mg, each pre-filled syringe contains 20 mg adalimumab in 0,4 ml (50 mg/ml) solution Reg.No. 51/30.1/0677. S4 AMGEVITA ® 40mg, each pre-filled syringe or pre-filled pen contains 40mg adalimumab in 0,8ml (50mg/ml) solution Reg.No. 51/30.1/0678. For full prescribing information refer to the professional information. Amgen South Africa (Pty) Ltd., Co. Reg. No.: 2011/112148/07. Building D, Ballyoaks Office Park, 35 Ballyclare Drive, Bryanston Ext. 7, 2021. Tel: 011 100 5300 Fax: 011 100 5301. Adverse Event Reporting email: safety-south-africa@amgen.com. Medical information email: medinfo-mea@amgen.com. Creation Date: 24 January 2022. PR-AMV-ZAF-000018-01-2022 Citrate-free formulation 3 For a less painful injection experience 4